Revelation Biosciences, Inc. (REVB)

NASDAQ: REVB · Real-Time Price · USD
2.440
-0.050 (-2.01%)
At close: Aug 1, 2025, 4:00 PM
2.599
+0.159 (6.51%)
After-hours: Aug 1, 2025, 7:56 PM EDT
-2.01%
Market Cap3.74M
Revenue (ttm)n/a
Net Income (ttm)-14.41M
Shares Out 1.53M
EPS (ttm)-108.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume89,287
Open2.450
Previous Close2.490
Day's Range2.380 - 2.480
52-Week Range2.106 - 168.000
Beta-0.08
Analystsn/a
Price Targetn/a
Earnings DateAug 12, 2025

About HEES

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in Janua... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 9
Stock Exchange NASDAQ
Ticker Symbol REVB
Full Company Profile

Financial Performance

Financial Statements

News

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (Nasdaq: REVB) the “Company” or “Revelation”) a clinical-stage life sciences company focused on rebalancing inflammation to opti...

9 days ago - Business Wire

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to op...

17 days ago - Business Wire

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reve...

4 weeks ago - Business Wire

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

2 months ago - Business Wire

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

2 months ago - Business Wire

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...

2 months ago - Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing infla...

3 months ago - Business Wire

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...

3 months ago - Business Wire

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

4 months ago - Business Wire

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

5 months ago - Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing infla...

5 months ago - Business Wire

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

5 months ago - Business Wire

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...

5 months ago - Business Wire

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 28, 2025, the Company will implement a 1-for-...

6 months ago - Business Wire

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

6 months ago - Business Wire

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the powe...

7 months ago - Business Wire

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the powe...

7 months ago - Business Wire

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

SAN DIEGO--(BUSINESS WIRE)---- $REVB #REVB--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power ...

8 months ago - Business Wire

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

8 months ago - Business Wire

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

SAN DIEGO--(BUSINESS WIRE)---- $REVB #FDA--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of tr...

9 months ago - Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power ...

9 months ago - Business Wire

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

11 months ago - Business Wire

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immuni...

1 year ago - Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of tr...

1 year ago - Business Wire

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

1 year ago - Business Wire